NCT07209176Recruiting
Physician- and Patient-based Barriers to NGS Testing
A Clinical Trial to Address Physician- and Patient-based Barriers to NGS Testing
Source: ClinicalTrials.gov · Last updated 3 Feb 2026
Brief summary (registry, in English)
The goal of this study is to improve next-generation sequencing (NGS) testing rates at Johns Hopkins in patients with metastatic prostate cancer. Investigators believe by targeting two barriers, provider-level and patient-level, will improve the testing rate of NGS at Johns Hopkins.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 256 (estimated)
- First submitted
- 30 Sept 2025
- Start date
- 6 Jan 2026
- Primary completion date
- 6 Sept 2027
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Diseases
- Prostate cancer
- NCT number
- NCT07209176
What you commit to
- Study type: Interventional
- Planned participants: 256
- From 6 Jan 2026 to the primary completion date, 6 Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \- Patients who have already had NGS testing performed.
Who the study is looking for
- men diagnosed with metastatic prostate cancer
- seen by Johns Hopkins Medical Oncology as a new patient visit between January 1, 2025 and December 31, 2026
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Coordinator of this site? Confirm its status | Baltimore | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.